Oppenheimer Says Raptor Pharma (RPTP) Procysbi Delay Immaterial, Reiterates Buy
Tweet
Share
E-mailGet Alerts RPTP Hot Sheet
Price: $9.00 --0%
Rating Summary:
6 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Pharmaceuticals (NASDAQ: RPTP) announced recently the FDA would delay the PDUFA date for Procysbi by three months.
Commenting on developments, analyst Boris Peaker of Oppenheimer said, "Although the delay is a near-term negative event, we do not believe that it has any implication on the FDA's ultimate decision about Procysbi. As such, we do not view this update as materially impacting the probability of approval or future commercial potential of Procysbi."
Peaker thinks near-term weakness may provide an attractive buying opportunity.
Oppenheimer has an Outperform rating on Raptor Pharmaceuticals (NASDAQ: RPTP) with a price target of $11.00.
For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $5.74 yesterday.
Commenting on developments, analyst Boris Peaker of Oppenheimer said, "Although the delay is a near-term negative event, we do not believe that it has any implication on the FDA's ultimate decision about Procysbi. As such, we do not view this update as materially impacting the probability of approval or future commercial potential of Procysbi."
Peaker thinks near-term weakness may provide an attractive buying opportunity.
Oppenheimer has an Outperform rating on Raptor Pharmaceuticals (NASDAQ: RPTP) with a price target of $11.00.
For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $5.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- UBS Reiterates Buy Rating on Hilton Worldwide (HLT)
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
